colorectal cancer
Conditions
Interventions
Case series:None
Sponsors
Cancer Hospital Affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with colorectal cancer who have been diagnosed for the first time or who have survived without tumor for more than 5 years and recurred; 2. Preoperative biopsy revealed adenocarcinoma, including classic and special types; 3. II - IV colorectal cancer that can be operated according to the evaluation of the investigator; 4. MSS type II patients with high risk factors can be operated. High risk factors include: T4, poor tissue blood differentiation (3/4 grade), vascular invasion, nerve invasion, preoperative intestinal obstruction or tumor site perforation, positive or unknown cutting edge, insufficient safe distance of cutting edge, and less than 12 lymph nodes; 5. All operable patients (pT1-4N+M0), including but not limited to patients with locally advanced rectal cancer who need preoperative radiotherapy and chemotherapy (CRT) or whole course neoadjuvant therapy (TNT); 6. Operative stage IV patients, including but not limited to patients with liver metastasis; 7. The results of gene detection of tumor tissue after surgery showed that any gene of KRAS/NRAS/BRAF/PIK3CA had a driving mutation (subject to the molecular diagnosis report of the hospital pathology department); 8. Patients who cooperate in collecting blood samples before operation can meet the requirements of gene detection; 9. Aged >= 18 years, male or female; 10. ECOG PS: 0-1; 11. Subjects volunteered to participate in the study and signed an informed consent form before the operation, with good compliance and regular blood sample acquisition.
Exclusion criteria
Exclusion criteria: 1. Complicated with other malignant tumors within 5 years; 2. Non primary colorectal cancer; 3. MSI-H stage II colorectal cancer; 4. Patients evaluated as pCR after preoperative conversion therapy or neoadjuvant chemotherapy; 5. Stage ? patients with multiple systemic metastases; 6. Unable to obtain enough tissue and blood samples for molecular detection; 7. According to the judgment of the researcher, the subject has other factors that may lead to the forced termination of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA; | — |
Countries
China
Contacts
Public ContactSun Yanlai
Affiliated Cancer Institute of Shandong First Medical University
Outcome results
None listed